Q3 Earnings Estimate for ASMB Issued By HC Wainwright

Key Points

• HC Wainwright predicts that Assembly Biosciences will report Q3 2025 earnings of ($0.50) per share, maintaining a "Buy" rating with a price target of $50.00.
• The company recently reported a Q2 loss of ($1.33) EPS, exceeding expectations with $9.63 million in revenue compared to the forecast of $5.30 million.
• Hedge funds have shown increasing interest in Assembly Biosciences, with JPMorgan Chase & Co. boosting their stake by 225.6% during the last quarter.

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Assembly Biosciences in a research note issued on Monday, August 18th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will post earnings per share of ($0.50) for the quarter. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at $0.87 EPS, Q4 2026 earnings at $0.86 EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at $1.67 EPS, FY2028 earnings at ($1.34) EPS and FY2029 earnings at $3.07 EPS.

Separately, Zacks Research raised shares of Assembly Biosciences to a "hold" rating in a research note on Tuesday, August 19th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $38.67.

Assembly Biosciences Stock Down 0.9%

NASDAQ:ASMB traded down $0.2370 during mid-day trading on Wednesday, reaching $26.6930. The company's stock had a trading volume of 34,590 shares, compared to its average volume of 40,348. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $27.17. The stock has a fifty day moving average of $19.80 and a 200-day moving average of $14.77. The firm has a market capitalization of $204.74 million, a PE ratio of -4.79 and a beta of 0.64.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.40. The company had revenue of $9.63 million for the quarter, compared to the consensus estimate of $5.30 million. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%.

Institutional Trading of Assembly Biosciences

A number of institutional investors have recently modified their holdings of ASMB. JPMorgan Chase & Co. boosted its holdings in shares of Assembly Biosciences by 225.6% in the 4th quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock valued at $180,000 after buying an additional 7,918 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Assembly Biosciences by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock valued at $1,495,000 after buying an additional 29,087 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after buying an additional 2,098 shares in the last quarter. Man Group plc bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at about $309,000. Finally, Palumbo Wealth Management LLC boosted its holdings in shares of Assembly Biosciences by 57.4% in the 1st quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company's stock valued at $172,000 after buying an additional 6,559 shares in the last quarter. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.